Joni3rs

🚨 IMPORTANT: Even if the FDA moves certain peptides to the compounding list, they remain prescription-only. You need documented medical justification. That’s why $hims launched Labs. These are Hims-tested biomarkers → and potential prescription peptide treatments if legally allowed: Elevated HbA1c (Hims Labs) → Low IGF-1 (Hims Labs) → CJC-1295 + Ipamorelin High CRP / inflammation (Hims Labs) → BPC-157 or TB-500 High cortisol / sleep markers (Hims Labs) → DSIP or Selank

@JerBearRN @wearehims @wearehers @novonordisk 😍😍

💊 $HIMS Coming soon…

@blury765 Ja Short report

Hab ich was $SOFI mäßig verpasst ? 😳

BREAKING: Analysts are quietly raising their $HIMS Q4 2026 revenue estimates. January: $705M Later: $715M Now: $763M

Joe Rogan talking about peptides, saying there’s no reason they shouldn’t be legal, other than pressure from big pharma.

🤫

So many saying they bought $HIMS at $15. Prove it or it didn't happen. Screenshots below... OR else its all BS

$HIMS up 8% with more than 3 hours to go before trading

BREAKING🚨: After just 3 trading days, this week is already the BIGGEST $HIMS trading volume ever, with 580M shares traded so far

Kind of sad I may never get the chance to buy $HIMS under $20 again

$HIMS now above 100M shares traded today, on track to become the 5th biggest trading day of all time

“$HIMS up 40% after Hours! You must be up huge, right?”

Hey Nurse, I’ve always respected your analysis and posts about $HIMS — whether they were positive or negative. You’ve raised many valid criticisms in the past. But lately it feels less like analysis and more like defending your position against Hims no matter what. The strongest move wouldn’t be countering every criticism of your views, but simply acknowledging that maybe you sold too early and continuing to analyze the company objectively — good news or bad

💊 $HIMS Unpopular opinion: Be careful ‼️ We have no actual details of this deal, it could have negative consequences to HIMS financials to avoid litigation risk ‼️ $HIMS filed a court extension last week in $NVO suit ‼️ $NVO has more leverage in these negotiations than $HIMS

🚨BREAKING : With the new $HIMS–Novo Nordisk partnership, not only is the lawsuit issue gone — more importantly, Hims will likely be one of the few telehealth providers able to offer the oral Wegovy pill.

🚨BREAKING: $HIMS shoots above $21, up 34% after the Novo Nordisk deal

IT HAPPENED!!! $hims $NOVO

🚨BREAKING: MyJuniper Germany ($HIMS) lists a Novo Nordisk GLP-1 weight-loss injection for 172€ (~$188) ZAVA Germany, also owned by $HIMS, offers it for 200€ (~$219)

@Donald04284612 💯💯

@Joni3rs $HIMS business model is so much better than $RO. $RO is basically a zero moat pure US business which will live and die by distribution agreements. $HIMS is a vertically integrated and disruptive powerhouse which will revolutionise the cash pay and wellness market globally.

$HIMS vs. Ro — 2025 Active countries: Ro: 1 (United States) Hims & Hers: 10 US DTC telehealth market share: Hims & Hers: 48% Ro: 25% Employees: Hims & Hers: 2,440 Ro: 750 Treatment categories: Hims & Hers: 7 Ro: 5

@JeppesenRj Why do you think it will Go down this year?

@Joni3rs Omg your mouth is talking your position…HIMS is expensive…at 15usd stille pe 45…and earnings will go down this year, I think 📉

🚨 IMPORTANT: Even if the FDA moves certain peptides to the compounding list, they remain prescription-only. You need documented medical justification. That’s why $hims launched Labs. These are Hims-tested biomarkers → and potential prescription peptide treatments if legally allowed: Elevated HbA1c (Hims Labs) → Low IGF-1 (Hims Labs) → CJC-1295 + Ipamorelin High CRP / inflammation (Hims Labs) → BPC-157 or TB-500 High cortisol / sleep markers (Hims Labs) → DSIP or Selank

@DividendCollect Schreiben längst schwarze Zahlen

Wie oft ich hier die letzten Tage über die Aktie von HIMS & Hers Health gelesen habe. Wahnsinn. 🤯 Kann mir jemand eine einfache Erklärung geben, wieso diese Aktie so gehyped wird? Bei $HIMS erinnere ich mich wieder zurück an die Corona-Zeit, in der die „Teladoc Health“-Aktie massiv angestiegen war und auf jeder Plattform von fast jedem hochgelobt wurde. Wo steht sie heute? -97% und vergessen! Ich will vorsichtig sein und das Unternehmen nicht direkt schlechtreden, aber was sind konkrete Gründe dafür, dass das Geschäftsmodell von $HIMS Zukunft hat? Welchen USP hat es? Wird das Unternehmen es irgendwann schaffen schwarze Zahlen zu schreiben? Ich lasse mich gerne eines besseren belehren. Sagt mir gerne was der „Investment Case“ ist.